Abstract: The invention discloses quinolinones which display inhibitory effects on serine proteases such as factor Xa, thrombin and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts and prodrugs of the compounds, pharmaceutically acceptable compositions comprising the compounds, their salts or prodrugs, and methods of using them a therapeutic agents for treating or preventing disease states in mammals characterized by abnormal thrombosis.
Type:
Grant
Filed:
December 15, 1998
Date of Patent:
February 15, 2005
Assignee:
Warner-Lambert Company LLC
Inventors:
Danette Andrea Dudley, Jeremy John Edmunds
Abstract: An antimicrobial compound, composition containing such compound, and method of use of the same for reducing the presence of microorganism on a substrate or in a fluid environment comprising an antimicrobial effective carrier and one or more essential antimicrobial compounds including non-halogenated naphthol compounds.
Type:
Grant
Filed:
May 20, 2003
Date of Patent:
January 4, 2005
Assignee:
Warner-Lambert Company LLC
Inventors:
David Scott Harper, Robert A. Coburn, Andre Soshinsky, Constantine Georgiades, Marianne D. Huntley
Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
Type:
Grant
Filed:
December 19, 2002
Date of Patent:
December 21, 2004
Assignee:
Warner-Lambert Company, LLC
Inventors:
Xue-Min Cheng, Noe Erasga, Gary Frederick Filzen, Andrew Geyer, Chitase Lee, Bharat Kalidas Trivedi
Abstract: The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.
Type:
Grant
Filed:
November 26, 2002
Date of Patent:
October 26, 2004
Assignee:
Warner-Lambert Company LLC
Inventors:
Lain-Yen Hu, Suzanne Ross Kesten, Huangshu Lei, Todd Robert Ryder, David Juergen Wustrow
Abstract: A process for synthesizing L and D-5,5,5,5′,5′,5′-hexafluoroleucine and protected analogs is disclosed. These compounds have utility in the preparation of fluorous peptides and proteins, which display interesting and unusual properties including strong self-association and an affinity for lipid bilayers.
Type:
Grant
Filed:
September 16, 2003
Date of Patent:
September 7, 2004
Assignees:
Warner-Lambert Company LLC, The Regents of the University of Michigan
Inventors:
James T. Anderson, Edward Neil Marsh, Peter Laurence Toogood
Abstract: A neuroprotective composition for protecting neuronal cells against oxidative stress and methods for using and preparing the same. More particularly, the neuroprotective composition of the invention comprises a therapeutically effective amount of ceruloplasmin or a functional derivative thereof. The neuroprotective composition is characterized in that it protects neuronal cells from reactive oxygen species such as •O2− and •OH. In a preferred embodiment, the neuroprotective composition further comprises an antioxidant consisting of catalase or of an amphiphilic physiological antioxidative solution comprising a mixture of pyruvate, antioxidant, and lipid(s) such as fatty acids. The neuroprotective composition could be used for the treatment of brain trauma, brain or cerebrovascular ischemia, neurodegenerative diseases, poisoning of neuronal cells, the diminution of drugs side effects and for preservation of neuronal grafts.
Type:
Grant
Filed:
November 5, 2001
Date of Patent:
August 24, 2004
Assignee:
Warner-Lambert Company LLC
Inventors:
Joanne Paquin, Mircea-Alexandru Mateescu, Éric De Grandpré
Abstract: The invention concerns Gelatin compositions for the use in pharmaceutical, veterinary, food, cosmetic or other products like films for wrapping food, aspics or jellies, preferably for predosed formulations like soft or hard gelatin capsules wherein the gelatin used is of non-bovine and non-pig origin and preferably derived from fish, poultry or plant sources. Especially preferred are film compositions for hard gelatine capsules prepared from fish gelatin.
Type:
Grant
Filed:
March 12, 2001
Date of Patent:
August 3, 2004
Assignee:
Warner-Lambert Company LLC
Inventors:
Robert Scott, Dominque Cadé, Xiongwei He
Abstract: A compound selected from those of formula (I):
wherein R1a, R1b, R2, R3, are as defined in the description, and optionally, its optical isomers, N-oxide, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of phosphosdiesterase-7 (PDE-7).
Type:
Grant
Filed:
March 27, 2003
Date of Patent:
June 22, 2004
Assignee:
Warner-Lambert Company LLC
Inventors:
Fabrice Vergne, Patrick Bernardelli, Edwige Lorthiois, Pierre Ducrot
Abstract: P-chiral bisphospholane ligands and methods for their preparation are described. Use of metal/P-chiral bisphospholane complexes to catalyze asymmetric transformation reactions to provide high enantiomeric excesses of formed compounds is also described.
Type:
Grant
Filed:
April 18, 2003
Date of Patent:
June 15, 2004
Assignee:
Warner-Lambert Company LLC
Inventors:
Garrett Stewart Hoge, II, Om Prakash Goel